🚀 Cytiva has launched its Sefia platform, developed with Kite, to accelerate the production of cell-based treatments.
💉 Sefia aims to help drug developers and healthcare providers produce CAR T therapies and other cell-based treatments more quickly and at a lower cost.
🏥 The platform offers greater automation, reducing the risk of errors and saving money.
🔬 Cytiva believes Sefia can reduce labor time and costs by up to 30%.
🌱 The platform is scalable and flexible, allowing it to be used in preclinical, clinical, and large-scale manufacturing.
💼 Cytiva will market Sefia directly to customers through its commercial organization.
💉 Sefia aims to help drug developers and healthcare providers produce CAR T therapies and other cell-based treatments more quickly and at a lower cost.
🏥 The platform offers greater automation, reducing the risk of errors and saving money.
🔬 Cytiva believes Sefia can reduce labor time and costs by up to 30%.
🌱 The platform is scalable and flexible, allowing it to be used in preclinical, clinical, and large-scale manufacturing.
💼 Cytiva will market Sefia directly to customers through its commercial organization.
📢 Revolutionary Sefia Platform Boosts Cell Therapy Production
Introduction:
Cytiva has launched its Sefia next-generation manufacturing platform in collaboration with Kite, a Gilead Company. The platform aims to accelerate the production of chimeric antigen receptor T-cell (CAR T) therapies and other cell-based treatments by incorporating more automation and reducing costs.
Main points:
- Cytiva’s Sefia platform is designed to help drug developers and healthcare providers increase the production of CAR T-cell therapies and other cell-based treatments.
- The platform was developed through a collaboration with Kite, a leading developer of CAR T therapies.
- Sefia offers greater automation compared to previous cell therapy platforms, reducing the risk of human error and batch failure in manufacturing.
- The platform has the potential to reduce labor time and cost by up to 30% and increase manufactured doses by up to 50% per year.
- Cytiva aims to offer a flexible and scalable platform that can be used for preclinical, clinical, and large-scale manufacturing of cell therapies.
Conclusion:
Overall, Cytiva’s launch of the Sefia next-generation manufacturing platform in collaboration with Kite has the potential to revolutionize the production of CAR T-cell therapies and other cell-based treatments. By incorporating more automation and reducing costs, the platform could accelerate the development and delivery of these therapies, leading to improved patient outcomes and increased accessibility.
